PT-141 (10 mg Vial) Dosage Protocol

Also known as: Bremelanotide

Enhances sexual desire and arousal through central nervous system pathways.

Dose range
500-1500 mcg daily
Route
Subcutaneous
Frequency
Once daily
Cycle length
8-16 weeks

PT-141, also known as Bremelanotide, is a synthetic peptide that works by activating melanocortin receptors in the brain to enhance sexual desire and arousal. This protocol outlines a subcutaneous dosing regimen that gradually increases over several weeks, typically ranging from 500 mcg to 1500 mcg daily.

  • Synthetic melanocortin receptor agonist (MC3R/MC4R).
  • Originally derived from Melanotan II.
  • FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women.
  • Enhances sexual desire by increasing dopamine release in brain reward pathways.
  • Typical protocol involves a gradual daily dose increase over 8-16 weeks.

Reconstitution

Vial strength

10 mg

Bacteriostatic water

3 mL

Concentration

3.33 mg/mL

1 unit = 0.01 mL = 33.3 mcg

  1. 1Draw 3.0 mL of bacteriostatic water with a sterile syringe.
  2. 2Inject the water slowly down the side of the vial, avoiding foaming.
  3. 3Gently swirl or roll the vial until the peptide is fully dissolved; do not shake.
  4. 4Label the vial with the reconstitution date and store it in the refrigerator, protected from light.

Dosing schedule

PhaseDoseOn a U-100 syringe
Weeks 1–8500 mcg (0.5 mg)15 units (0.15 mL)
Weeks 9–121000 mcg (1.0 mg)30 units (0.30 mL)
Weeks 13–161500 mcg (1.5 mg)45 units (0.45 mL)

Protocol detail

StartBegin with 500 mcg daily for the initial 8 weeks to evaluate tolerance.
EscalateIncrease the dose to 1000 mcg daily during Weeks 9–12 if well-tolerated.
TargetIf still well-tolerated, further increase to 1500 mcg daily for Weeks 13–16.
FrequencyInject once per day subcutaneously.
TimingInject at a consistent time each day; rotate injection sites between the abdomen and thighs.

Overview at a glance

GoalSupport sexual desire and arousal by activating central melanocortin receptors.
ScheduleDaily subcutaneous injections for 8–12 weeks (can extend to 16 weeks).
Dose Range500–1500 mcg daily with gradual titration.
Reconstitution3.0 mL of bacteriostatic water per 10 mg vial (~3.33 mg/mL) for accurate unit measurements.
StorageFreeze lyophilized; refrigerate reconstituted peptide; avoid repeated freeze–thaw cycles.

How it works

Bremelanotide is a synthetic peptide that mimics the natural alpha-melanocyte-stimulating hormone. It primarily acts on MC3R and MC4R melanocortin receptors in the brain, leading to increased dopamine release in areas associated with reward and arousal, such as the nucleus accumbens. This central mechanism enhances sexual motivation and desire. Unlike some other treatments, PT-141 does not directly influence the nitric oxide pathway but can indirectly stimulate nitric oxide production in penile tissue in men. It may cause temporary side effects related to peripheral MC1R agonism, such as elevated blood pressure or skin darkening.

Reported effects

  • Improved sexual desire scores in women with HSDD
  • Reduced distress associated with low sexual desire
  • Potential for improved erectile responses in men
  • Increased subjective arousal in women

Reported side effects

  • Nausea (most common, often transient)
  • Flushing
  • Headache
  • Injection-site reactions
  • Transient increases in blood pressure
  • Skin darkening (hyperpigmentation)

Storage

Lyophilised (unmixed)

Store at -20 °C (-4 °F) in dry, dark conditions; minimize moisture exposure.

After reconstitution

Refrigerate at 2–8 °C (35.6–46.4 °F); use within approximately 30 days and avoid freeze–thaw cycles.

Supplies

Peptide vials (PT-141, 10 mg each)Approx. 3 vials for 8 weeks (28 mg total), 6 vials for 12 weeks (56 mg total), or 10 vials for 16 weeks (98 mg total).
Insulin syringes (U-100)1 syringe per day; 56 for 8 weeks, 84 for 12 weeks, or 112 for 16 weeks.
Bacteriostatic water (10 mL bottles)Approx. 1 bottle for 8 weeks (9 mL needed), 2 for 12 weeks (18 mL needed), or 3 for 16 weeks (30 mL needed).
Alcohol swabs2 per day (vial stopper + injection site); ~2 x 100-count boxes for 8-12 weeks, 3 x 100-count boxes for 16 weeks.

Important notes

  • This guide is for educational purposes only and not medical advice.
  • Always use new, sterile insulin syringes (27–30G, 5/8-inch needle) for each injection and dispose of them in a sharps container.
  • Systematically rotate injection sites (abdomen, thighs) to prevent lipodystrophy or irritation.
  • Inject slowly and wait a few seconds before removing the needle to ensure proper absorption.

Frequently asked questions

How quickly should I expect to see results from PT-141?

Individual responses may vary. Clinical trials showed significant improvements in sexual desire over several weeks of use. The gradual dosing protocol is designed to assess tolerance and allow for an incremental increase in effect.

What should I do if I experience nausea after injecting PT-141?

Nausea is a common and usually transient side effect. Starting with a lower dose and gradually increasing it as outlined in the protocol can help mitigate this. If nausea persists or is severe, consult with a healthcare professional.

Can PT-141 be used by men?

While FDA-approved for HSDD in premenopausal women, studies have explored PT-141's potential in men for improving erectile responses and sexual arousal. This protocol is general and individual results in men may vary.

Is intranasal administration of PT-141 an option?

PT-141 was initially studied via the intranasal route but was ultimately approved for subcutaneous injection due to higher and more consistent bioavailability, and fewer transient side effects like increased blood pressure, compared to intranasal delivery.

Educational reference only. These figures summarise how PT-141 is commonly described in research literature and supplier documentation, including the PT-141 listing at peptidesuk4u.co.uk. They are not a prescription, not medical advice, and not a recommendation to self-administer anything.

Related protocols

Back to all protocols